15 results for author:"Pollock P.M." in Literature citations
Results Customize
› Repeat search in UniProtKB (2)
| FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. Byron S.A., Gartside M., Powell M.A., Wellens C.L., Gao F., Mutch D.G., Goodfellow P.J., Pollock P.M. PLoS ONE 7:e30801-e30801(2012) · Mapped (21) |
| Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. Wortmann A., He Y., Christensen M.E., Linn M., Lumley J.W., Pollock P.M., Waterhouse N.J., Hooper J.D. J. Biol. Chem. 286:42303-42315(2011) · Mapped (10) |
| p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Terzian T., Torchia E.C., Dai D., Robinson S.E., Murao K., Stiegmann R.A., Gonzalez V., Boyle G.M., Powell M.B., Pollock P.M. et al. Pigment Cell Melanoma Res 23:781-794(2010) · Mapped (51) |
| Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Kalinina J., Byron S.A., Makarenkova H.P., Olsen S.K., Eliseenkova A.V., Larochelle W.J., Dhanabal M., Blais S., Ornitz D.M., Day L.A. et al. Mol. Cell. Biol. 29:4663-4678(2009) · UniProtKB (1) · Mapped (2) |
| Active Notch1 confers a transformed phenotype to primary human melanocytes. Pinnix C.C., Lee J.T., Liu Z.J., McDaid R., Balint K., Beverly L.J., Brafford P.A., Xiao M., Himes B., Zabierowski S.E. et al. Cancer Res. 69:5312-5320(2009) · Mapped (3) |
| A crystallographic snapshot of tyrosine trans-phosphorylation in action. Chen H., Xu C.F., Ma J., Eliseenkova A.V., Li W., Pollock P.M., Pitteloud N., Miller W.T., Neubert T.A., Mohammadi M. Proc. Natl. Acad. Sci. U.S.A. 105:19660-19665(2008) · UniProtKB (1) |
| Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Byron S.A., Gartside M.G., Wellens C.L., Mallon M.A., Keenan J.B., Powell M.A., Goodfellow P.J., Pollock P.M. Cancer Res. 68:6902-6907(2008) · Mapped (3) |
| Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk. Zhao Z.Z., Pollock P.M., Thomas S., Treloar S.A., Nyholt D.R., Montgomery G.W. Hum. Reprod. 23:1661-1668(2008) · Mapped (12) |
| Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Pollock P.M., Gartside M.G., Dejeza L.C., Powell M.A., Mallon M.A., Davies H., Mohammadi M., Futreal P.A., Stratton M.R., Trent J.M. et al. Oncogene 26:7158-7162(2007) · Mapped (12) |
| p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Qin J.Z., Stennett L., Bacon P., Bodner B., Hendrix M.J., Seftor R.E., Seftor E.A., Margaryan N.V., Pollock P.M., Curtis A. et al. Mol. Cancer Ther. 3:895-902(2004) · Mapped (35) |
| Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Pollock P.M., Cohen-Solal K., Sood R., Namkoong J., Martino J.J., Koganti A., Zhu H., Robbins C., Makalowska I., Shin S.S. et al. Nat. Genet. 34:108-112(2003) · Mapped (3) |
| PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Pollock P.M., Walker G.J., Glendening J.M., Que Noy T., Bloch N.C., Fountain J.W., Hayward N.K. Melanoma Res. 12:565-575(2002) · Mapped (3) |
| High frequency of BRAF mutations in nevi. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J. et al. Nat. Genet. 33:19-20(2003) · Mapped (3) |
| Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines. Pollock P.M., Hayward N. Melanoma Res. 12:183-186(2002) · Mapped (6) |
| A homologue of the Drosophila Son of sevenless gene maps to mouse chromosome 17. Yulug I.G., Egan S.E., Pollock P.M., Fisher E.M. Genomics 18:733-734(1993) · Mapped (3) |